Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imeglimin QT/QTc study in healthy subjects
NCT02924337Phase 1Completed
- Sponsor
- Poxel SA
- Start
- Sep 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of imeglimin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Poxel SA. Primary endpoint: Change from baseline in QTcF (deltaQTcF) at 24 hours. Started Sep 2016; status: completed.
02
Drugs
imeglimin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02924337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02924337.